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Highlights  
 
● D187N gelsolin variant is responsible for the most common form of AGel amyloidosis 
● We obtained the crystal structure of the second domain of D187N in complex with a 
nanobody 
● D187N substitution increases the conformational flexibility of the protein 
● Nanobody binding shifts D187N towards a native-like conformation 
● The same nanobody binds to and protects other gelsolin pathological variants (N184K and 
G167R) 
● The nanobody protects from the toxicity induced by gelsolin mutants in C. elegans 
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Abstract 
AGel amyloidosis, formerly known as familial amyloidosis of the Finnish-type, is caused by 
pathological aggregation of proteolytic  fragments of plasma gelsolin. So far, four mutations in the 
gelsolin gene have been reported as responsible for the disease. Although D187N is the first 
identified variant and the best characterized, its structure has been hitherto elusive. Exploiting a 
recently-developed nanobody targeting gelsolin, we were able to stabilize the G2 domain of the 
D187N protein and obtained, for the first time, its high-resolution crystal structure. In the 
nanobody-stabilized conformation, the main effect of the D187N substitution is the impairment of 
the calcium binding capability, leading to a destabilization of the C-terminal tail of G2. However, 
molecular dynamics simulations show that in the absence of the nanobody, D187N-mutated G2 
further misfolds, ultimately exposing its hydrophobic core and the furin cleavage site. The 
nanobody's protective effect is based on the enhancement of the thermodynamic stability of 
different G2 mutants (D187N, G167R and N184K). In particular, the nanobody reduces the 
flexibility of dynamic stretches, and most notably decreases the conformational entropy of the C-
terminal tail, otherwise stabilized by the presence of the Ca
2+
 ion. A Caenorhabditis elegans-based 
assay was also applied to quantify the proteotoxic potential of the mutants and determine whether 
nanobody stabilization translates into a biologically relevant effect. Successful protection from G2 
toxicity in vivo points to the use of C. elegans as a tool for investigating the mechanisms underlying 
AGel amyloidosis and rapidly screen new therapeutics.  
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1. Introduction 
AGel amyloidosis (AGel) is a neglected disease caused by deposition of gelsolin (GSN) amyloids 
and described for the first time in Finland in 1969 [1]. For a long time, AGel has been associated 
with the substitution of a single residue of the protein, D187 in the protein second domain (G2) 
(Figure 1), to either N or Y [2,3]. It has also been considered an endemic pathology in Finland and 
named Familial Amyloidosis, Finnish-type (FAF). Nowadays, AGel is the preferred name for this 
disease [4], as new cases have been gradually reported from many other countries demonstrating its 
worldwide occurrence.  
In the last five years, the broader clinical use of genetic tests and the raised awareness of this class 
of diseases led to the identification of three new AGel forms. A new classification of the disease 
into three different types, according to the GSN sequence and the organ(s) involved in amyloid 
deposition, has been therefore proposed and includes: i) a systemic form, caused by D187N and 
D187Y mutations, respectively known as the Finnish- and Danish-variant; ii) a kidney localized 
form, associated with the deposition of GSN, either full-length or as fragments, carrying N184K or 
G167R mutation [5–7]; and iii) a sporadic form, caused by wild-type (WT) GSN deposits 
surrounding a sellar glioma of the hypophysis [8]. All AGel types share the lack of effective 
pharmacological therapies that cure the disease targeting the source of toxicity, rather than acting 
only as palliative, symptomatic treatments.  
Among the listed GSN variants, the D187N protein is the best biochemically and biophysically 
characterized. More than 20 years of in vitro and in vivo studies led to a consensus on the 
pathological mechanism underlying Finnish AGel type, although this model has been questioned by 
recent findings [9]. According to this model, aspartic acid 187 is part of a cluster of residues in the 
G2 domain of GSN, able to chelate a calcium ion [10]. Its N or Y substitution compromises calcium 
binding [11–14], leading to the exposure of an otherwise buried sequence, which is recognized by 
the furin protease [15]. In the Golgi, this intracellular enzyme cleaves GSN producing a C-terminal 
68 kDa fragment (C68). C68 is later exported to the extracellular space where it is further processed 
by matrix metalloproteases, eventually producing 5 and 8 kDa highly amyloidogenic peptides [16]. 
These fragments rapidly aggregate and deposit in different tissues and organs [17,18]. In stark 
contrast to the extensive biochemical knowledge available on the D187N mutant, its crystal 
structure has never been obtained, limiting the mechanistic understanding of GSN instability and 
aberrant proteolysis.  
This study aims at characterizing the crystal structure of the isolated G2 domain (Figure 1) of the 
D187N protein (D187NG2) by exploiting a recently-developed nanobody (Nb) targeting GSN [19]. 
Different Nbs able to bind mutated GSN and to detect or prevent its aggregation, have been 
developed and tested[19–22]. Among them, Nb11 proved to be the most efficient one. Studies 
performed in vitro and in vivo demonstrated that Nb11 binds G2 domain of GSN with high affinity, 
irrespective of calcium, and protects the mutated domain from furin proteolysis, thus skipping the 
first event of the aberrant proteolytic cascade (19–22). Inspired by the recent use of Nbs as an 
unique tool for structural biological studies [23], we employed Nb11 to increase the stability of 
D187NG2. 
The successful co-crystallization of D187NG2 in complex with Nb11 (D187NG2:Nb11)  showed that 
the nanobody protects D187NG2 from furin-induced proteolysis, stabilizing the G2 C-terminal 
linker. Such stabilization is achieved allosterically since the Nb11 binding site locates far from the 
furin cleavage site. We complemented the structural results cross-referencing molecular dynamics 
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(MD) simulations insights with thermal denaturation studies and furin proteolysis assays. These 
studies were extended to other mutations causing AGel, such as G167R and N184K.  
In the absence of cellular or animal models recapitulating G167R and N184K-related AGel as well 
as the toxicity of the WT or mutated G2 domains, we decided to employ the invertebrate nematode 
Caenorhabditis elegans as “biosensor”, able to recognize proteins which exert in vivo a biologically 
relevant effect [24–27]. This approach takes advantage of the ability of the pharynx of worms, 
fundamental for their feeding and survival, to be inhibited when it meets molecules acting as 
chemical stressors [28]. This nematode-based method has been widely applied to recognize the 
toxicity of different amyloidogenic proteins in vivo, demonstrating that singular molecular 
mechanisms underlie their proteotoxic activity  [24–27,29]. The protein folding, oligomerization 
propensity and the exposure of hydrophobic residues on the outside of the protein are relevant for 
the toxic action of β-amyloid (Aβ) and HIV-matrix protein p17 [25,27,29]. Instead, amyloidogenic 
cardiotoxic light chains are recognized as stressors by C. elegans  thanks to their ability to interact 
with metal ions and continuously generate reactive oxygen species [24,26]. 
Our findings indicate that C. elegans efficiently recognizes the proteotoxic potential of the G2 
domains and can discriminate between different level of toxicity. Furthermore, the stabilizing 
effects induced by Nb11 on G2 translated into an effective protection in vivo. These observations 
point to the use of this nematode-based model as a valuable tool for investigating the mechanisms 
underlying AGel. 
 
Figure 1: Domain architecture of plasma gelsolin and sequence of the G2 domain. The G2 construct 
comprises residues 151 to 266 around the second domain of full-length plasma gelsolin (residue numbering 
excludes the signal peptide). Secondary structure elements (α0 to α2, β1 to β5) are indicated below the 
sequence; calcium-coordinating residues are marked in green, and known amyloidosis-causing amino-acid 
mutations (D187N object of this study, as well as D187Y, G167R, N184K) are boxed. Vertical bars indicate 
the locations of aberrant processing by furin and matrix metallo-proteases (MMP), ultimately leading to 
fibril formation and AGel. 
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2. Materials and methods 
2.1 Protein production  
If not otherwise stated, all chemicals are from Sigma-Aldrich (Merck Millipore Ltd., Tullagreen, 
Carrigtwohill, Co. Cork, IRL) and of the best available purity. All preparative and analytic 
chromatographies were performed on a ÄKTA pure 25 system  (GE Healthcare, Uppsala, Sweden) 
using prepacked columns from the same company. 
2.1.1 Gelsolin expression and purification 
Constructs and expression conditions for GSN variants as isolated G2 domain or full-length 
proteins were performed as already reported [30,31]. The here named G2 refers to the shorter G2s 
construct in [30] and spans residues 151-266 of the GSN, according to the mature plasma isoform 
(Figure 1). Purification followed the protocol previously described [30]. ΔG2 construct for the 
expression of WTΔG2 harbours a WT sequence but lacks the first beta-strand (β1); it spans residues 
168-266 and it is purified following the same protocol developed for the other G2 domains [31]. 
Briefly, G2 domains were passed through a Ni-chelating column (HisTrap) and gel filtered in a 
Superdex 75 following the removal of the His-tag. Full-length proteins went through three 
chromatographic steps without cleaving the N-terminal tag, HisTrap, MonoQ and gel filtration on a 
Superdex 200. G2 domains were stored in a 20 mM HEPES solution, pH 7.4, containing 100 mM 
NaCl and 1 mM CaCl2 whereas full-length GSN in 20 mM HEPES solution, pH 7.4, containing 100 
mM NaCl, 1 mM EDTA and 1 mM EGTA. Whenever required proteins were concentrated or 
buffer-exchanged in centrifugal filters Amicon
®
 Ultra (Merck Millipore Ltd., Tullagreen, 
Carrigtwohill, Co. Cork, IRL) with cutoffs of either 10k or 30k. 
2.1.2 Nb11 expression and purification 
The synthetic gene coding for Nb11 [19] fused to the thrombin cleavage site and 6xHis tag at the C-
terminus was purchased by Eurofins genomics (Ebersberg, Germany). The sequence was optimized 
for E. coli codon usage and the gene cloned in a pET11 vector (Merck Millipore Ltd., Tullagreen, 
Carrigtwohill, Co. Cork, IRL). Tagged Nb11 was produced in SHuffle
®
 T7 E. coli cells (New 
England BioLabs Inc., Ipswich, USA) grown in LB medium. Once OD at 600 nm reached the value 
of 0.6, the expression of the gene was induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside 
and cells harvested by centrifugation 16 h after incubation at 20 °C. Cells were resuspended in 20 
mM Na2PO4, pH 7.4, containing 500 mM NaCl (supplemented with DNase I and cOmplete™ 
Protease Inhibitor Cocktail), lysed with a Basic Z Bench-top cell disruptor (Constant system Ltd., 
UK) operating at 25 kPsi and centrifuged at 38,000 RCF. The clarified crude extract was loaded on 
a 5 ml HisTrap and Nb11 eluted stepwise with the lysis buffer supplemented with 500 mM 
imidazole. Fractions enriched in Nb11 were passed through a Superdex 75, equilibrated with 20 
mM HEPES, pH 7.4, 100 mM NaCl. 
2.2 Crystallization, structure solution and analysis 
2.2.1 Crystallization 
D187NG2:Nb11 complex for crystallization experiments was prepared by mixing equimolar 
amounts of the individual protein. The complex was loaded on a Superdex 75 increase (equilibrated 
with 20 mM HEPES, 100 mM NaCl, 1 mM CaCl2, pH 7.4), obtaining a single peak, consistent with 
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the theoretical molecular weight of the complex, which was concentrated to 12 mg/ml in the same 
buffer. This sample was used for extensive crystallization screening using an Oryx-8 crystallization 
robot (Douglas Instruments Ltd, UK) and several commercial solutions in a sitting-drop set up. The 
purified complex (0.15/0.25 μl) was mixed with 0.25/0.15 μl of the reservoir solutions. Two 
different conditions yielded crystals after 2-6 days at 20 °C, namely (i) 0.1 M potassium 
thiocyanate, 30 % poly(ethylene glycol) methyl ether 2000 and 4.0 M sodium formate and (ii) 0.1 
M potassium phosphate, pH 6.2, 10% (v/v) glycerol and 25% v/v 1,2 propanediol. Crystals were 
soaked with the respective reservoir solution supplemented with 20% glycerol, flash-frozen in 
liquid N2 and diffraction data were collected at beamline ID23-1 (European Synchrotron Radiation 
Facility, Grenoble, France).  
2.2.2 Data processing, structure solution, refinement and analysis 
The two datasets (orthorhombic and tetragonal crystals grown in condition (i) and (ii), respectively) 
were processed with XDS [32], scaled with Aimless [33], and the structures solved by molecular 
replacement using the program phaser [34] and the PDB: 4S10 as the searching model. The 
orthorhombic structure (1.9 Å) was refined with phenix.refine [35] and manual model building was 
performed with COOT [36]. The final coordinates were deposited in the RCSB database with 
accession code PDB: 6H1F. The tetragonal structure (2.4 Å) could be refined only partially due to 
the poor quality of the diffraction (see Table 1 for the complete data collection and refinement 
statistics). The structural analysis was performed using the orthorhombic structure, except where 
indicated; all of the figures were prepared with either PyMOL or VMD [37,38]. 
All the other structures used for the B factor analysis were subjected to 3 cycles of refinement with 
phenix.refine. B factors for the WTG2:Nb11 and D187NG2:Nb11 were averaged between 
asymmetric molecules or between datasets, respectively. The rest of the analysis was performed as 
reported earlier [39]. 
2.3 Molecular dynamics (MD) simulations 
The crystal structure of G2 domain in complex with Nb11 (PDB: 4S10) was used to build the initial 
configuration for MD runs. The structure editing and building facilities provided by the HTMD 
software package [40] were used to construct a set of systems by selecting either the G2 domain 
only (chain D of the original PDB file) or the domain together with the bound Nb11 (chains D and 
B). In silico mutations were applied to restore residues 226 and 228 to their WT amino acids, to 
generate the D187N and N184K systems, and to remove the coordinated Ca
2+
 ion where 
appropriate. The titratable side chains and initial H bond network were then optimized at pH 6.5 via 
the proteinPrepare procedure of HTMD [41]; systems were solvated with transferable 
intermolecular potential with 3 points (TIP3P) water at 100 mM NaCl ionic strength and 
parameterized with the CHARMM36 force field [42]. The systems thus prepared were minimized 
and equilibrated for 4 ns in constant pressure conditions at 1 atm, yielding orthorhombic boxes with 
a water buffer of at least 15 Å per side. All simulations were conducted via the ACEMD software 
with a timestep of 4 fs, particle-mesh Ewalds long-range electrostatics treatment and the hydrogen 
mass repartitioning scheme [43].  
Each system was set for a production run in the number volume temperature (NVT) ensemble. 
Simulations of the G2 system without Nb11 were completely unrestrained and therefore the 
globular domain was free to diffuse in the solvent. To obtain a more efficient simulation box for the 
G2:Nb11 elongated complex while still preventing self-interactions with periodic images, its 
rotational diffusion was restricted by restraining Cα atoms of the Nb11‟s secondary structure 
elements with a harmonic force of 0.025 kcal/mol/Å
2
. No restraint was applied to the G2 domain, 
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nor to the contact region of Nb11. Runs were interrupted at 800 ns or when the full solvation of the 
C-terminus caused its extension outside of the simulation box. The WTG2:Nb11 simulation was also 
truncated at 750 ns because the complex became transiently unbound. Local conformational 
flexibility was assessed computing the root-mean-square fluctuation (RMSF) of backbone atoms, 
aggregated by residue; values are reported as the equivalent B factors according to the equation 
B=8π2/3 RMSF2.  
 
2.4 Thermal stability  
2.4.1 Circular Dichroism (CD) spectroscopy 
CD measurements were performed with a J-810 spectropolarimeter (JASCO Corp., Tokyo, Japan) 
equipped with a Peltier system for temperature control. All measurements were performed on 15 
µM G2, Nb11, or the complex in 20 mM HEPES solution containing 100 mM NaCl and 1 mM 
CaCl2 at pH 7.4. Temperature ramps were recorded from 10°C to 95°C (temperature slope 50 °C/h) 
in a 0.1 cm path length cuvette and monitored at 218 nm wavelength.  
2.4.2 Thermofluor 
Thermodynamic stabilities were also evaluated in the presence of Sypro Orange, a fluorogenic 
probe unspecifically binding hydrophobic surfaces and with excitation/emission spectra compatible 
with standard qPCR machines. WT and mutated G2 domains with or without equimolar Nb11, were 
diluted to 1 mg/ml in 20 mM HEPES solution containing 100 mM NaCl and 1 mM CaCl2, pH 7.4. 
Each solution was mixed with 3 μl of a 1/500 (v/v) dilution of Sypro Orange , in a total volume of 
20 µl. Fifteen µl of each sample were transferred to multiplate
®
 PCR Plates, sealed with Microseal
® 
„B‟ Film, and analysed in triplicate in an MJ MiniTM Thermal Cycler (hardware and consumables 
from Bio-Rad Laboratories Inc., Hercules, USA). The temperature was increased from 10 °C to 100 
°C in 0.2 °C steps with 10 s equilibration before each measurement. Fluorescence intensity was 
measured within the excitation and emission wavelength ranges of 470–505 and 540–700 nm, 
respectively. Tm was calculated as the minimum of the first-derivative of the traces using the 
manufacturer software and the value is reported as the average of triplicate measures. 
2.5 Furin assay 
Furin cleavage assays were performed in a total volume of 30 µl, using 1 U of commercial furin 
enzyme  (New England BioLabs Inc., Ipswich, Massachusetts, USA) and 1 mg/ml of full-length 
WT and mutated GSN in 20 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.5, containing 100 mM 
NaCl and 1 mM CaCl2 in the presence or absence of 1 mg/ml of Nb11 (roughly 1:6 GSN:Nb11 
molar ratio). To monitor the susceptibility to proteolysis, 12 μl aliquots of the reaction mix were 
collected right upon addition of furin and 3 h after incubation at 37 °C. The reaction was blocked by 
adding to each sample 4 µl of Sodium Dodecyl Sulphate (SDS) loading buffer 4X (BioIO-RadAD 
Laboratories Inc., Hercules, USA) supplemented with 0.7 M β-mercaptoethanol and by incubation 
at 90 °C for 3 min. Proteolysis reaction was monitored by SDS - PolyAcrylamide Gel 
Electrophoresis using ExpressPlus™ PAGE (12%) and the provided running buffer (GenScript 
Biotech Corp., USA ). 
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2.6 Proteotoxicity studies on C. elegans  
Bristol N2 strain was obtained from the Caenorhabditis elegans Genetic Center (CGC, University 
of Minnesota, Minneapolis, MN, USA) and propagated at 20°C on solid Nematode Growth 
Medium (NGM) seeded with E. coli OP50 (CGC) for food. The effect of G2 domains on 
pharyngeal behavior was evaluated as already described [27]. Briefly, worms were incubated with 
1-1000 μg/ml of G2 domains (100 worms/100 μl) in 2 mM HEPES solution containing 1 mM NaCl 
and 0.1 mM CaCl2, pH 7.4. Equimolar concentrations of WTG2 or WTΔG2 (18 µM, corresponding to 
250 μg/ml of WTG2) were administered to worms in the same conditions. Hydrogen peroxide (1 
mM) was administered in dark conditions as a positive control. After 2 h of incubation on orbital 
shaking, worms were transferred onto NGM plates seeded with OP50 E. coli. The pharyngeal 
pumping rate, measured by counting the number of times the terminal bulb of the pharynx 
contracted over a 1-minute interval, was scored 2 and 24 h later. Control worms were fed 2 mM 
HEPES solution containing 1 mM NaCl and 0.1 mM CaCl2, pH 7.4 (Vehicle) only. To evaluate the 
protective effect of Nb11, worms were fed for 2 h G2 domains alone (250 µg/ml for WTG2 and 
D187NG2 and 100 µg/ml for N184KG2 and G167RG2, corresponding to 19 and 8 μM, respectively), 
8-19 μM Nb11 alone, or G2 domains previously pre-incubated for 10 min at room temperature 
under shaking conditions with equimolar concentration of Nb11 to allow the formation of the 
complex. Nematodes were then transferred to NGM plates seeded with fresh OP50 E. coli and the 
pumping rate was scored after 2 and 24 h. Worms were also exposed to Vehicle in the same 
experimental conditions. 
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3. Results 
3.1 Crystal structure of the D187NG2:Nb11 complex 
Crystals of the isolated D187NG2:Nb11 complex readily appeared in different conditions, allowing 
the collection of two X-ray diffraction datasets of different quality. Particularly, the crystal grown 
in condition (i) above, belonging to the P212121 space group, diffracted to 1.9 Å resolution, and the 
one that appeared in condition (ii), belonging to the P41212 space group, diffracted to 2.4 Å. The 
resulting models are hereafter referred to as the orthorhombic and tetragonal structure, respectively 
(Figure 2); the complete list of the data collection and refinement statistics is reported in Table 1. 
Due to the difference in quality of the data, the orthorhombic structure is used to infer the impact of 
the D187N mutation on the GSN structure (Figure 2), unless otherwise stated. 
 
  Orthorhombic Tetragonal 
PDB ID 6H1F — 
Data collection     
  Space group P 21 21 21 P 41 21 2 
  Cell dimension: a, b, c (Å) 33.8, 46.8, 132.1 77.0, 77.0, 88.8 
  Unique reflections 17,289 10,995 
  Resolution range (Å) 
46.8-1.9 
(1.94-1.90) 
46.4-2.4 
(2.49-2.40) 
  CC1/2 0.990 (0.714) 0.999 (0.800) 
  Completeness (%) 99.8 (99.9) 100 (100) 
  Multiplicity 5.1 16.9  
Refinement     
  Resolution range (Å) 44.1-1.9 46.4-2.4 
  Rwork / Rfree (%) *  19.9/23.3 18.6/26.0 
  RMSD     
    Bonds (Å) 0.006 0.008 
    Angles (º) 0.786 0.964 
  Ramachandran plot     
    In preferred regions (%) 96.0 95.7 
    Outliers (%) 0.0 0.4 
  B-factors (Å
2
) 
§ 
30 66 
 
Table 1: Data collection and refinement statistics. Notes: Values in parentheses refer to the 
highest resolution shell. * Rwork = Σhkl||Fo| - |Fc|| ⁄ Σhkl|Fo| for all data, except 10%, which were 
used for Rfree calculation.  
§ 
Average temperature factors over the whole structure. 
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Both the structures obtained confirm that Nb11 binds the G2 domain over an extended area 
including the β5-loop-α2 region (residues 230-234, 238-245) and the loop-β4 stretch (residues 193-
198) as already observed for WT gelsolin (PDB: 4S10, [19]). The binding region is opposite from 
the aberrant cleavage site (residues 168-172), which had previously raised suspicions of a 
crystallographic artifact. The structures obtained here rule out this hypothesis, since it is unlikely 
that three different crystal packings (WTG2:Nb11 belongs to P1 space group) artificially stabilize 
the same assembly (Figure 2A). Thus, the 3D structures of G2:Nb11  appear unable to explain how 
the binding to Nb11 in a distal area could shield G2 from furin proteolysis without additional data.  
The second remarkable feature of the WTG2 and D187NG2 assemblies is that the G2 structures are 
almost identical (root mean squared deviation, RMSD, 0.25 Å over 90 Cα atoms). Besides, two 
striking differences were observed: the absence of the coordinated calcium ion, and a shorter stretch 
of ordered C-terminal segment in D187NG2 (Figure 2A). In the C-terminus of mutated G2, we could 
only model up to residue 258 and 255 in the orthorhombic and tetragonal structure, respectively 
(Figure 2A), suggesting that the remaining stretch of the protein is highly flexible and invisible to 
X-rays (the last resolved amino acid in WTG2 is 261). The disorder prediction algorithm MobiDB-
lite [44] indeed reports a putative disordered region around residues 220-258 owing to its poly-
ampholitic character (Supplementary Figure S1). Besides the C-terminus, all residues are modelled 
but a few side chains of the Nb11 chain (namely V2, K65 and L128). 
The superimposition of the orthorhombic structure of D187NG2 to that of the WTG2 (PDB: 1KCQ), 
shows no major conformational changes (as is the case for the G167R variant) nor the 
rearrangement of the hydrogen bond network in the core of the domain in the N184K variant, unlike 
it was observed for the other G2 mutants (Figure 2B). Residues G186, D187 and E209 of the 
calcium-coordinating cluster show remarkable conformational conservation (D259, the fourth 
residue of the cluster, lies in the unresolved C-terminal stretch).  
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Figure 2: Crystal Structure of the complexes formed by WT or D187N Gelsolin G2 domains with the 
Nb11 nanobody. A) The overall structure of the D187NG2:Nb11 complexes compared to the WTG2:Nb11. 
Complexes are represented in cartoon and colored blue/cyan (orthorhombic D187NG2:Nb11), green/light 
green (tetragonal D187NG2:Nb11) and red/orange (PDB:4S10, WTG2:Nb11); the calcium ion is shown as a 
green sphere. The C-terminal residues unresolved in the D187N structures are arbitrarily displayed by a 
dashed grey line. B) Superimposition of the D187NG2 domain extrapolated from the orthorhombic structure 
with the WTG2 (PDB:1KCQ). Residues of the calcium cluster (green sphere) and those found altered in the 
N184K structure are shown as sticks. WT and D187N variants share high structural similarity (RMSD: 0.25 
Å over 90 Cα atoms).  
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3.2 Impact of the D187N mutation on the structure of the G2 
domain 
A large body of evidence indicates that the presence of D187N mutation mainly affects the ability 
to bind the calcium ion [11–14]. In WTG2 the calcium binding site is a highly polar cavity delimited 
by the protein core, the side chain of K166 and the C-terminal tail (Figure 3A, left). The ion is 
pentacoordinated by the side-chains of residue D187, E209 and D259 and by the main-chain O 
atom of G186. The site is open to the solvent on the side opposite to K166, where two ordered 
water molecules are visible in the WTG2 structure (Figure 3A, left). 
In the orthorhombic structure of D187NG2, although the overall geometry of the calcium binding is 
maintained, some differences are visible. The residue D259 could not be modeled and the presence 
of a water molecule in its place (bound to the O atom of T257) shows that the residue is extruded 
from the cavity. Two more water molecules are found overlapping neither with the calcium ion nor 
with other solvent molecules present in the WTG2 structure. The side-chain of K166 also undergoes 
small rearrangements: its amino tip becomes more flexible, based on the quality of the electron 
density, and the interaction with residues 187 and 259 is either lost or weakened. The N187-K166 
distance is 4.6 Å, whereas 3.1 Å separate D187 from K166 in the WTG2 due to a stronger polar 
interaction (Figure 3A, middle). This small reorganization of the calcium binding residues, as well 
as the lack of the coordinated ion, are sufficient to create a small cavity (Figure 3A, right, computed 
by PyMOL [37]), a known source of instability in proteins [45]. Even though this cleft is solvent-
exposed and accessible, the high concentration of its acidic residues might be the force driving the 
stretching of both D259 residue and the whole C-terminal tail.  
The same cavity is fully open in the tetragonal structure of D187NG2, where we were able to model 
only up to residue 255. The electron density for the calcium site is of poor quality (data not shown), 
the side-chain of K166 is barely visible and no solvent molecule could be modelled. The 
orthorhombic and tetragonal structures seem to represent two intermediate states toward the 
domain‟s (partial) unfolding.   
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Figure 3: Impact of the D187N mutation on the structure of the gelsolin G2 domain.  A) Details of the 
calcium binding site in the WTG2 (yellow, PDB: 1KCQ) and D187NG2 (blue). Electron density is contoured at 
1.5 σ. The cavity volume induced by D187N substitution was generated by PyMOL and is shown in yellow. 
B) Reorganization of the H-bond network in the C-terminal “arm” of the domain of the D187NG2 variant 
(blue cartoon and sticks) in comparison with the WTG2 (yellow). In 1KCQ cadmium substitutes the 
physiological ion; here it is labelled as calcium for readability (Ca
2+
, green sphere); ordered water 
molecules playing a structural role in the respective regions are represented as red spheres 
 
 
3.3 Nb11 binding modulates C-terminal disorder allosterically 
Based on our structures, one can hypothesize that Nb11 binding induces D187NG2 in a proteolysis-
resistant conformation,  but crystallographic analysis alone is not sufficient to assess whether the 
flexibility of the D187NG2 C-terminal tail and exposure of the calcium cavity lead to its 
susceptibility to furin proteolysis. To investigate the impact of the mutation on local kinetics or a 
possible conformational selection effect by Nb11 binding, we analyzed the domain's dynamics via 
MD simulations. We simulated the WTG2 and D187NG2 systems in the presence or absence of 
bound Nb11 (Table 2), starting from the crystallographic poses reported in PDB: 4S10 (see 
Methods section). 
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Sample Nb11 Ca
2+
 
Simulated 
time (ns) 
C-terminal 
disorder onset 
WTG2 - + 800  Not observed 
WTG2 + + 750  Not observed 
D187NG2 - - 748  After 83 ns 
D187NG2 + - 512  After 40 ns 
 
Table 2: Summary of the molecular dynamics runs. Simulated time and behavior of the C-terminal stretch 
are reported. "C-terminal disorder onset" indicates the time of onset of C-terminal segment mobility (residue 
248 and beyond), defined as R186-T260 distance > 20 Å. Afterwards, the C terminal segment ("arm") is 
solvated and strongly fluctuating. 
 
The most striking result was the fast opening and solvent-exposure of the C-terminus segment, 
which occurred within the first hundred nanoseconds, in all of the structures of D187NG2 lacking 
the Ca
2+
 ion (Table 2). In the crystallographic structures of the WTG2 protein, the C-terminal region 
up until residue 259 lies near the β1-β2 hinge loop which hosts the furin cleavage site (R169-V-V-
R172), indicating a possible steric protection mechanism already suggested by Huff et al. [14]. In 
consistency with our crystallographic results, MD did not uncover further major “static” structural 
rearrangements between the WTG2, D187NG2 and D187NG2:Nb11 in the timescales tested.  
Local (residue-wise) fluctuations across the G2 residues (Figure 4A, red curve) indicate two major 
areas of destabilization in the D187NG2 with respect to the WTG2, namely (a) the region 179-183 
(helix α0) is located; and (b) the arm of the domain, i.e. the C-terminal region up to residue 240 
including the β5-α2 loop, the α2 helix and the opening C-terminal arm plus its elbow at helix α2. 
Binding of Nb11 to the D187NG2 (Figure 4A, cyan curve) almost entirely abolished the fluctuations 
in both regions. In other words, Nb11 essentially restores the fluctuation dynamics of the mutant to 
the low level present in the WTG2. The simulation of the WTG2:Nb11 complex confirmed that the 
Nb11 does not significantly alter the local stability of the WTG2, although it partially stabilizes the 
β5-α2 region where it binds. 
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Figure 4: Dynamics and fluctuations of the D187NG2 variant in the presence or absence of Nb11. A) Plot 
of the static B factors per residue calculated by the simulation of the WTG2 and D187NG2 in the presence 
(cyan line) or absence (red) of Nb11. Structured regions are indicated in blue (β sheets from β1 to β5) and 
pink (α helices α0 to α2). Furin cleavage site is in the β1-β2 loop. B) Normalized B factors (Bz-score) extracted 
by the crystallographic structures of WTG2, WTG2:Nb11 and D187NG2:Nb11, color-coded as in panel A. C) 
Overview of the main molecular features and conformational diversity observed during the simulations of 
D187NG2 in the presence or absence of Nb11 (light grey). Dark grey: snapshots of the disordered C-terminus 
from the conformational ensemble. 
 
The main molecular events underlying the destabilization induced by the D187N mutation are 
summarized in Figure 4C. In the absence of Nb11, the fluctuations in D187NG2 lead to the already 
described flexibility of the C-terminal tail with the increase of its entropy. Then the transient 
displacement of the α2 helix occurs, followed by the disruption of the hydrophobic core triad 
composed by W180, F183 and W200 residues (Supplementary Figure S2). Noteworthy, the 
ConSurf algorithm indicates that F183, belonging to the α0 helix, is strongly conserved in gelsolin-
like domains (see Discussion) [46]. Even though binding of Nb11 has only a minor impact on the 
resolved pose of the C-terminal tail, its conformational entropy was  reduced compared with 
D187NG2 alone, thus likely preventing the rearrangement of the α2 helix and the exposure of the 
core residues. 
To validate the computational findings, we further compared the amount of disorder obtained from 
the simulations with the crystallographic data. Although not ideal to investigate protein dynamics, 
crystallographic data in the 2 Å resolution range does contain information on the disorder and 
mobility of the single atoms in the crystal [47]. To this purpose, B factors shown in Figure 4B were 
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extracted from the structures of D187NG2:Nb11, WTG2 (PDB: 1KCQ) and WTG2:Nb11 (PDB: 4S10) 
(the structure of the D187NG2 variant alone is unavailable). B values were averaged between 
datasets or symmetric molecules (where available) and normalized to zero mean and unit variance 
in order to obtain a Bz-score comparable between models (Figure 4B). As expected, we observe a 
sharp decrease of WTG2 and D187NG2 Bz-score at the Nb11 binding interface, indicating that this 
region becomes less dynamic. Stabilization also propagates through the C-terminus and the α2 helix 
(that is partly involved in the interaction with Nb). The hinge loop formed by amino acid residues 
167-170, which hosts the sequence recognized by furin, results very dynamic in both WTG2 and 
D187NG2 structures (with and without Nb11) suggesting that the presence of the mutation does not 
directly affect the conformation or the stability of this loop. 
The MD analysis identified two instability hotspots in the mutated G2 domain: the α0 helix and the 
stretch comprising β5-α2 loop and α2 helix. In the first region we were not able to detect any 
significant differences between the structure of the WTG2 and that of D187NG2 stabilized by Nb11 
(data not shown). As shown in Figure 3B (left panel), the WTG2 β5-α2 loop is connected to the C-
terminal tail and the calcium binding site through a solvent-mediated H-bond network. The 
structure of the mutant reveals a reorganization of the polar contacts mostly due to a drift of the 
backbone in the 235-239 stretch and the different conformation of side-chains of residues 185 and 
236 (Figure 3B, right panel). Overall, these observations indicate that the D187N substitution 
causes a slight loss in connectivity of the G2 domain essentially due to the loss of the coordinated 
Ca
2+
. Major rearrangements observed in the simulations are thus likely prevented by the binding to 
Nb11, which partly compensates for the loss of the calcium ion and forces the first half of the C 
terminus of D187N in a WT-like conformation. 
3.4 Nb11 protects all pathogenic GSN variants from aberrant 
furin proteolysis  
The ability of Nb11 to bind D187N-mutated GSN and to inhibit its proteolysis by furin has been 
extensively demonstrated in vitro and in vivo [19]. Recently, we have characterized two novel GSN 
pathogenic variants reported as responsible for a renal localized amyloidosis, G167R and N184K 
[30,31]. Structural and functional analyses revealed that the N184K substitution induces a 
reorganization of the connection in the core of the G2 domain; contrarily, G167R mutation 
promotes the dimerization of the protein by a domain swap mechanism. Similarly to D187N, both 
substitutions impair protein stability and ultimately lead to protein degradation and aggregation. 
Therefore, we wondered if Nb11 would also be able to bind the variants responsible for the renal 
disease and protect these proteins against furin proteolysis. The susceptibility to furin proteolysis of 
full-length WT and the three aforementioned mutants was tested in the presence or the absence of a 
6-fold molar excess of Nb11. 
Full-length activated (i.e. calcium-bound) GSN is a flexible protein prone to unspecific proteolysis, 
a phenomenon that is more evident for the mutants (Figure 5, band marked with *). Its 
susceptibility to furin cleavage was therefore tested over a short incubation time (3 h) at 37 °C. 
Furin activity produces two fragments, the well-known C68 and one here named N17, which is 
visible only when proteolysis proceed to a larger extent, as is the case for the G167R variant. Nb11 
dramatically reduced the susceptibility to furin of all the tested variants, either abolishing any trace 
of its activity, or significantly slowing down the process. 
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Figure 5: Effect of Nb11 on the susceptibility of full-length GSN variants to proteolysis. 
Susceptibility to furin proteolysis of WT, D187N, N184K and G167R variants in their full-length 
form evaluated in the presence (+) or the absence (-) of Nb11. C68 and N17 are the two fragments 
produced by furin activity, named after their molecular weight in kDa. * Indicates unspecific 
proteolysis product due to contaminants.  
 
3.5 Nb11 stabilizes the mutated G2 fold  
The protection exerted by Nb11 on the furin proteolysis cannot be simply explained by steric 
hindrance. Moreover, our structural and computational analyses pointed at a stability modulation 
effect. To further elucidate the molecular mechanism underlying the action of the nanobody, we 
assayed Nb11‟s impact on the thermal stability of the G2 variants. Denaturation of the proteins was 
induced by a linear temperature gradient (from 20°C up to 90°C) and studied by CD spectroscopy at 
218 nm (sensitive to α-helical content) in the presence of saturating calcium concentration. WTG2 
and all the mutated domains showed a sigmoidal increase in ellipticity upon unfolding 
(Supplementary Figure S3). Contrarily, Nb11 signal decreased over time as the immunoglobulin-
like domain lacks α-helical content. Interpretation of the melting curves of the complexes is 
therefore hindered by the opposing behavior of the two proteins.  
To analyze CD data, we compared the denaturation curve obtained for the G2:Nb11 complex with 
the arithmetical sum of the experiments performed on the individual subunits of the complex. We 
hypothesize that, in the case there is no stabilization, the curve of the complex should roughly 
superimpose to the curve of the sum, because the G2 domain and Nb11 unfold independently. 
Indeed, this was the behavior observed for the WTG2 , in which the binding to Nb11 seems not to 
have any impact on the protein stability (Figure 6A). In contrast, all the pathological G2 mutants 
showed significant differences between the denaturation profile of the sum and that of the 
experimental complex (Figure 6A). 
 
 
  WTG2 G167R G2 N184K G2 D187N G2 
- Nb11 
Tm (°C) 60.3±0.6 47.7±0.6 43.0±0.0 44.0±1.7 
ΔTm (WTG2-mutant)  12.6 17.3 16.3 
+ Nb11 Tm (°C) 577±0.6 54.6±0.6 53.0±1.0 53.7±0.6 
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ΔTm (WTG2-mutant)  3.1 4.7 4.0 
 
Table 3: Quantitative evaluation of the effect of Nb11 on the thermal stability of G2 domains. Apparent Tm 
values from thermofluor experiments were calculated as the minimum of the first derivative of the traces in 
Figure 6B. Reported values are the average of three independent measurements ± SD, at most. Tm  for Nb11 
alone in the same experimental conditions is 50 ± 1 °C. 
 
To quantify the stabilizing effect of Nb11, we performed thermofluor experiments of the G2 
domains, whose denaturation is achieved in the presence of a fluorogenic probe (Figure 6B). As 
reported in Table 3, the Tm values for the mutated G2 domains were lower than that of the WTG2 
with differences between the Tm value of WTG2 and that of the mutated proteins (ΔTm) ranging from 
12.6°C to 17.3°C. These results are similar to those previously reported, measured by CD (see 
supplementary Table 1) [10,14,30,31]. The WTG2:Nb11 complex unfolds at a lower temperature 
than the WTG2 alone, suggesting the absence of any stabilization induced by Nb11. On the contrary, 
mutants‟ thermal stability significantly benefits from Nb11 binding as indicated by the ΔTm values 
which dropped to 3.1-4.7 °C (Table 3).  
In agreement with the structural observations, these data show that Nb11 protects G2 from aberrant 
proteolysis reverting the destabilization induced by the mutations. It is noteworthy that both Tm 
experimental approaches are insensible to the displacement of the C-terminal tail, because it neither 
results in a loss of secondary structures nor it leads to the exposure of hydrophobic patches, being 
the calcium pocket very polar. 
 
 
Figure 6: Thermodynamic stabilities of mutated G2s in the presence or absence of Nb11. A) Unfolding 
profiles, followed by CD spectroscopy, of WTG2, D187NG2, N184KG2 and G167RG2 in complex with Nb11 
(red trace)  is compared with the arithmetical sum of Nb11 alone + individual G2s (dashed cyan line). B) 
G2s alone (blue trace) and G2s in complex with Nb11 (red) are analyzed in thermofluor experiments. 
Thermal stability is measured by SYPRO orange fluorescence, which yields sigmoidal curves typical of a 
two-state, cooperative denaturation.  
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3.6 Nb11 counteracts the proteotoxicity of G2 domains in C. 
elegans 
It is well known that the administration to nematodes of a toxic compound, such as a misfolded 
protein, induces a pharyngeal dysfunction [24,25,28,29] that can be evaluated by counting the 
number of worm‟s pharyngeal contractions, defined as “pumping rate” [28]. Therefore, we 
employed C. elegans assays to determine whether the structural changes and the stabilizing effects 
induced by Nb11 on the mutated G2 variants can also affect their biological properties.  
First, we evaluated the ability of WTG2 or mutated G2 to induce a pharyngeal dysfunction in 
worms. To this end, 250 µg/ml of each protein was administered to worms, and the pharyngeal 
contraction was determined at different times after the treatment. After 2 h the pumping rate of 
WTG2-fed worms is significantly reduced compared to those fed vehicle (228.4 ± 1.7 and 217.1 ± 
1.6 pumps/min for vehicle- and WTG2-fed worms, respectively) (Figure 7A). A greater inhibition 
was observed in nematodes treated with mutated G2 domains, particularly N184KG2 (177.9 ± 1.8 
pumps/min) which is significantly more toxic than G167RG2 and D187NG2 variants (191.6 ± 2.3 and 
208.4 ± 3.0 pumps/min, respectively) (Figure 7A). These outcomes were comparable to those of 
worms treated with 10 mM hydrogen peroxide, used as positive stress control (183.7 ± 1.6 
pumps/min, p<0.0001 vs vehicle, Student‟s t-test), indicating that the reduction of pharyngeal 
contraction induced by the mutated G2 domains is biologically relevant.  
We also observe that the pharyngeal impairment induced by WTG2 is transient because the pumping 
rate scored 24 h after the administration was similar to that of vehicle-fed nematodes (233.4 ± 2.3 
and 225.8 ± 1.7 pumps/min for vehicle and WTG2, respectively). On the contrary, the mutated G2 
domains induced a persistent pharyngeal functional damage, without complete recovery even after 
24 h (Figure 7B). Whereas the pharyngeal dysfunction induced by D187NG2 did not change over 
time (208.4 ± 3.8 and 211.3 ± 3.5 pumps/min at 2 and 24 h, respectively), those caused by G167RG2 
and N184KG2 significantly decreased (Supplementary Figure 4). 
Trying to establish a relationship between protein toxicity and folding, worms were fed with 
equimolar concentration of either WTG2 or WTΔG2. Lacking the β1 strand, WTΔG2 is unable to 
properly fold and displays spectroscopy characteristics typical of a natively unfolded protein under 
physiological conditions [31].  We observed that the unfolded G2 domain (WTΔG2) was 
significantly more effective in reducing the pharyngeal pumping than the folded one underlining the 
relevance of the folding status for the toxicity (Supplementary Figure 5). 
The different toxic potential of the mutated G2 domains is further proven by the experiments 
evaluating their dose-dependent effects on the pharynx of worms (Figure 7C-D). IC50 (half-maximal 
effect) values calculated 2h after the exposure resulted significantly higher for WTG2 than for 
mutated G2 and, among these, the higher toxicity was obtained for N184KG2 (Table 4). Similar IC50 
values are calculated after 24 h for G167RG2 and D187NG2 whereas a 4-fold increase is observed for 
N184KG2 (Table 4).  
These findings indicate that C. elegans can efficiently recognize the proteotoxic potential of G2 
domains, pointing to its use as a rapid and valuable tool to investigate the mechanisms underlying 
AGel. Also, the different proteotoxic abilities exerted by the various mutated G2 domains suggests 
that each mutation may drive a specific damage. 
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The effect of Nb11 on the pharyngeal toxicity induced by the G2 domains was then investigated. 
For these experiments, worms were fed 250 µg/ml of WTG2 or D187NG2 (corresponding to 19 µM), 
100 µg/ml of N184KG2 or G167RG2 (corresponding to 8 µM), concentrations close to the IC50 value 
calculated for the 2h of exposure (Table 3). G2s were administered alone or as complexes with an 
equimolar concentration of Nb11. Although Nb11 alone caused a significant reduction of the 
pharyngeal function, both its toxicity as well as those of G2 domains scored 2 h after administration 
were neutralized when co-administered (Figure 7E). Noteworthy, the effect of Nb11 on the toxicity 
induced by the mutated G2 domains were still present 24 h after the treatment (Supplementary 
Figure 6) as an indication of sustained protective action.  
These data indicate that the structural and molecular effects induced by Nb11 on the G2 variants 
can translate into a biologically relevant effect in vivo. Nb11 can bind and chaperone the D187NG2 
as well as the G2 domains of the renal variants counteracting their proteotoxic potential. 
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 IC50 (µg/ml) ± SE                                              
Treatment 2 hours       24 hours 
WTG2 398.5 ± 1.12 Not interpolated 
D187NG2 273.0 ± 1.09 * 241.8 ± 1.24  
N184KG2 79.7 ± 1.12 **** 334.5 ± 1.19 ° 
G167RG2 133.9 ± 1.20 ***  170.2 ± 1.21   
 
Table 4: Pumping rates and IC50 values of WT and mutated G2 domains. IC50 values were calculated from 
the dose-response curves (Figure 7C/D). * p<0.05, ***p<0.0005 and **** p<0.0001 vs. WT, ° p<0.05 vs. 
G167R, one-way ANOVA and Bonferroni post-hoc test.   
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Figure 7. Proteotoxic effect of the G2 domains and the protective effect of Nb11. Worms fed for 2 h vehicle 
(2 mM Hepes solution containing 1 mM NaCl and 0.1 mM CaCl2, pH 7.4) or 250 µg/ml WTG2, D187NG2, 
G167RG2 or N184KG2. Pharyngeal pumping was scored (A) 2h and (B) 24h after treatment by counting the 
number of pharyngeal contractions in one minute (pumps/minute). Data are mean ± SE (N=30 
worms/group). ** p<0.001 and **** p<0.0001 vs. Vehicle, § p<0.05 and §§ p<0.001 vs. WT, °°° p<0.0005 
and °°°° p<0.0001 vs. N184K, one-way ANOVA and Bonferroni’s post hoc test (C-D) Dose-response effect 
of 1-1000 μg/ml  of the different G2 domains scored (C) 2h and (D) 24h after the administration. E) G2 
domains (250 µg/ml of WT and D187N or 100 µg/ml of N184K and G167R, corresponding to 19 or 8 μM 
respectively) were incubated with an equimolar concentration of Nb11 (19 or 8 μM) for 10 min at room 
temperature under shaking conditions. Nb11 (19 or 8 μM) and G2 domains (100-250 µg/ml) alone were also 
administered. Vehicle (2 mM Hepes solution containing 1 mM NaCl and 0.1 mM CaCl2, pH 7.4) was used as 
negative control. The solutions were then administered to C. elegans (100 µl/100 worms). The pharyngeal 
activity was determined 2h after treatment by determining the number of pharyngeal bulb contraction 
(pumps/min). Data are mean ± SE (N=30 worms/group). *** p<0.0005 and ****p<0.0001 vs Vehicle 
without Nb11, °°°° p<0.001 and °°° p<0.005 vs the corresponding sample without Nb11, according to one-
way ANOVA and Bonferroni’s post hoc analysis. Nb11 treatment significantly protected from the toxicity 
induced by all WT and mutated G2 domains (interaction p<0.001 , two-way ANOVA and Bonferroni’s post 
hoc analysis). 
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4. Discussion 
The current model of the pathological mechanism underlying AGel amyloidosis is mostly based on 
studies performed on the D187N-mutated protein and experiments conducted in vitro and in vivo on 
transgenic animals expressing this variant [15,16,48]. Results obtained with D187N likely also 
apply to the later discovered Danish variant (D187Y), although some differences were reported 
[49]. On the contrary, the mechanism underlying the recently discovered renal disease associated 
with the N184K and G167R mutations have not been fully elucidated. Interestingly, while the 
crystallographic structures of isolated G2 domains carrying the N184K or G167R mutation are 
already available [30,31], until now the D187N/Y structural characterization had not been 
elucidated.  
We here demonstrated that crystallization of the D187N G2 domain was possible only in complex 
with a previously developed nanobody, called Nb11 [19]. Nb11 tightly binds to gelsolin and 
protects the D187N variant from aberrant furin proteolysis. In the analysis of the crystal structure, 
we must consider that the binding of Nb11 somehow biases our model. Indeed, we are observing a 
proteolysis-resistant species that lost, to some extent, the structural determinants of its 
proteotoxicity.  
To elucidate the mechanism of protection exerted by Nb11 it is necessary to understand the 
pathological mechanism of D187N mutation (and vice versa). Clearly, Nb11 acts as a protective 
chaperone; however, the molecular mechanism behind such function was as yet unclear, mainly 
because Nb11 binds G2 in a position distant from the furin cleavage site (Figure 2). Regarding the 
D187N mutation, a large body of literature is already available, and these studies converged to a 
general agreement, i.e. that the D187N substitution disrupts calcium binding in G2 and the 
thermodynamic stability of the mutant is decreased to levels similar to those of the WT protein 
deprived of calcium [10–12,49]. Ultimately the mutation leads to the exposure of an otherwise 
buried sequence, which is aberrantly cleaved by furin. However, the correlation between calcium 
binding impairment and susceptibility to proteolysis has been the object of discussion. One 
hypothesis is that the mutation somehow induces a conformational change of the native state that 
leads to the exposure of the furin site. Another possibility is that the loss of coordinated calcium 
increases the population of (partially) unfolded protein, which is generally prone to proteolysis [10–
12,49]. The partial disorder hypothesis is consistent with the crystallographic structures, the 
thermodynamic data as well as with the MD results, which in the absence of the coordinated cation 
show a fast (on a timescale of tens of ns) opening of the C-terminal stretch. Calcium-mediated 
disorder-to-order induction has been shown, e.g. in sortase [50,51], adenylate cyclase toxin [52], 
and possibly several others [53,54]. 
Interestingly, Kazmirsky and coworkers came to a similar conclusion through a detailed NMR 
analysis of the D187N variant [12]. In the study, they suggested that the C-terminal tail of the 
pathogenic variant might be less structured compared to the WT. It might be tempting to explain the 
increased susceptibility to proteolysis solely based on the flexibility of the C-terminus, which 
indeed interacts with the hinge loop and exerts some steric protection. However, even the 
crystallographic structures of the D187NG2:Nb11 complex reveal a destabilized tail, and the 
simulations show a similar dynamic behavior of the stretch irrespective of Nb11 binding. 
Destabilization of the C-terminus might likely be a necessary condition, but it seems not to be 
sufficient for the efficient proteolytic cleavage. 
In conclusion, we believe that the destabilization of the C-terminal tail is the direct consequence of 
the loss of the Ca
2+
 ion induced by D187N mutation. Such increased flexibility is the first event that 
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triggers the sequential opening of the gelsolin fold, which results in the exposure of residues of the 
hydrophobic core. The process is likely reversible and this partially unfolded state of the protein is 
susceptible to furin proteolysis. In the complex with Nb11, the binding interface, including α0 and 
α2-loop-β5, becomes more rigidly anchored to the proper WT conformation. The latter Nb11-
stabilized region lies at the base of the disorder-prone C terminus, forming an elbow of sorts. We 
speculate that Nb11 stabilization reverses, at least in part, the entropy gain due to the abolished 
coordination of Ca
2+
. 
Even though Nb11 was raised against WT gelsolin, it was shown to bind the D187N variant as well, 
with a slightly lower affinity [19]. Crystallographic structures of N184K and G167R variants, as 
isolated G2 as well, are also available [30,31]. N184K neither impairs calcium binding nor it 
significantly destabilizes the C-terminal tail. Loss of conformational stability of N184K-mutated G2 
comes from the rearrangement of the polar contacts, which the mutated residue is part of, in the 
core of the domain. As for the D187N/Y case, N184K mutation eventually leads to furin 
proteolysis. Contrarily, the pathological mechanism underlying the G167R-dependent disease is 
still to be fully elucidated. An alternative amyloidogenic pathway has in fact been proposed based 
on the observation that this variant dimerizes via a domain-swap mechanism [31]. At the same time, 
even the G167R mutant is prone to aberrant proteolysis and shows impaired thermal stability.  
The WTG2 and D187N- and N184K-mutated variants share a high structural conservation. The 
Nb11 binding interface of the G167RG2 variant is not affected by its dimerization. As a 
consequence, it comes as no surprise that Nb11 binds the renal variants with similar efficiency. On 
the contrary, the protection from proteolysis of the N184K and G167R mutants would have been 
difficult to predict because the impact of these substitutions on the G2 dynamics as well as the 
mechanism of destabilization is significantly different.  
We tested Nb11 protection of the renal variants in standard furin assays and observed indirect 
inhibition of the protease activity comparable to that of the D187N variant. To further investigate 
this aspect, we aimed at testing Nb11‟s activity on mutated G2 in a more biological context. As 
neither an animal nor a cell model of renal AGel amyloidosis is currently available, we employed a 
nematode-based assay already developed and validated by our group and already successfully used 
to determine the toxicity of different amyloidogenic proteins and investigate the mechanisms 
underlying their proteotoxic effect [24–27,29]. This is based on the knowledge that the rhythmic 
contraction and relaxation of the C. elegans pharynx, the organ fundamental for the worm‟s feeding 
and survival, is sensitive to molecules that can act as “chemical stressors” such as some proteins 
induced in stress conditions. We here showed for the first time that all isolated G2, at 
concentrations similar to those observed as circulating in humans [55] can cause a biologically 
relevant toxic effect recognized by C. elegans. Whereas WTG2 only induced a transient reduction of 
the pharyngeal pumping, all the pathological mutants caused an impairment which persisted still 
after 24 hours, suggesting that these proteins caused a permanent tissue damage. 
Interestingly, Nb11, which was able to bind and chaperone all the disease-causing mutant forms of 
GSN and prevent their aberrant proteolysis, completely abolished the proteotoxic effects induced by  
G2 domains in worms. Although the mechanisms underlying the ability of C. elegans to recognize 
G2 domain as toxic remains to be elucidated, these findings are consistent with the hypothesis  that 
the toxicity can be ascribed to the partially unfolded status of the proteins and that Nb11 hides the 
structural determinant of toxicity. The involvement of the folding status in G2 toxicity was further 
assessed by using a protein totally unfolded due to the truncation of residues 151-167. The toxic 
effect caused by WTΔG2 protein on the pharynx of worms was greater and more persistent than that 
observed with the folded  WTG2. Additional studies are required to fully elucidate the mechanisms 
underlying the toxicity of G2 domains on the C. elegans pharynx. 
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The knowledge of high-resolution determinants of D187N toxicity and the therapeutic action of 
Nb11 may contribute to the ongoing efforts in the expansion of the currently limited landscape of 
therapeutic interventions against FAF and other amyloidosis-related diseases. The use of the C. 
elegans-based assay for the evaluation of the proteotoxic potential of the G2 domains offers 
unprecedented opportunities to investigate the molecular mechanisms underlying the AGel forms 
caused by different GSN variants. This model can also be employed for rapidly screen the 
protective effect of novel or repurposed drugs thus accelerating the identification of an effective 
therapy against AGel amyloidosis. 
5. Conclusions 
Nb11 works as a pharmacological chaperone (sometimes referred to as pharmacoperone), a concept 
originally formulated in the context of small chemicals, rather than macromolecules. Such 
chaperones restore mutated proteins' function or prevent misfolding, either stabilizing the native 
fold, or assisting the folding process. Although the pharmacoperone concept has been around for a 
while, only a limited number of successful examples can be found in literature [56–58], and very 
few drugs belonging to this family are available on the market. Nb11 is, in our knowledge, the first 
case of a pharmacoperone-like nanobody whose efficacy has been proven in vivo. Contrary to other 
previously developed pharmacological chaperones, which are mutation-specific, Nb11 protects all 
gelsolin pathological variants identified so far, irrespective of the different pathways or mechanisms 
leading to their degradation and/or aggregation. Furthermore, disease-causing mutations yield 
proteins which are at times difficult to express and purify, due to their solubility, instability or 
toxicity. Our data show that pharmacological chaperones can be developed using the WT protein as 
a target, aiming at the stabilization of the native-like conformation, thus increasing the number of 
diseases that can be potentially tackled with an analogous strategy.  Wide-spectrum applicability is 
of pivotal importance in view of the potential application of Nbs in therapy.  
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